InvestorsHub Logo
Followers 0
Posts 9
Boards Moderated 0
Alias Born 09/28/2006

Re: None

Thursday, 07/06/2017 3:59:21 PM

Thursday, July 06, 2017 3:59:21 PM

Post# of 3283
One month from hearing 2nd quarter results. Should include an update on the Poziotinib compassionate use patient. Throw in an enrollment update on Rolontis. Possibly news on a partner (EU?). Downside potential - possibly raising cash to pay off convertible notes, which wouldn't necessarily be a bad thing but would likely be viewed as negative in the short term. Other things anyone? Guesstimates on the revenue for 2nd quarter?